Clinical characteristics of dermatologic manifestations of COVID‐19 infection

Clinical characteristics of dermatologic manifestations of COVID‐19 infection

This article co-authored by Cromos Pharma CEO Dr Vlad Bogin and published in the International Journal of Dermatology (3 July 2020) examines the dermatologic manifestations of COVID-19. It includes a case series of 15 patients, review of literature, and proposed etiological classification. Read the full article here

CONTACT

INQUIRY@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS

Rezdiffra Approval | Cromos Pharma
Rezdiffra Approval Sheds Light on the Challenges of NASH Diagnosis and Fibrosis Identification
Clinical Trials in Georgia 2024 | Cromos Pharma
Сlinical Trials in Georgia 2024
Clinical Research Focus 27bth Edition April | Cromos Pharma
Clinical Research Focus. 27th Edition
The Impact of US-China Tensions on Biopharmaceutical Innovation | Cromos Pharma
Navigating the Challenges: The Impact of US-China Tensions on Biopharmaceutical Innovation
Hungary Country Profile 2024 | Cromos Pharma
Exploring Clinical Trial Opportunities: Hungary’s 2024 Country Profile
World Kidney Day 2024 | Cromos Pharma
World Kidney Day 2024
Clinical Research Focus 26th edition | Cromos Pharma
Clinical Research Focus. 26th Edition
Celebrating Rare Disease Day 2024 | Cromos Pharma
Celebrating Rare Disease Day 2024
Clinical Research Focus 25th edition | Cromos Pharma
Clinical Research Focus. 25th Edition
The FDA’s Latest Guidance on Human Genome Editing | Cromos Pharma
Navigating the Future of Gene Therapy
Regulatory Updates and Simplified Processes in Türkiye | Cromos Pharma
Türkiye’s Emerging Role in Clinical Research: Regulatory Updates and Simplified Processes
J.P. Morgan Healthcare Conference 2024 Key Insights | Cromos Pharma
J.P. Morgan’s Healthcare Conference: A Glimpse into the Optimistic Pulse of 2024
Pragmatic Clinical Trials in 2024 | Cromos Pharma
Pragmatic Clinical Trials in 2024
Clinical Research Focus 24th edition | Cromos Pharma
Clinical Research Focus. 24th Edition
Key Insights from ASH 2023 | Cromos Pharma
Exploring Groundbreaking Advances: Key Insights from ASH 2023
Key Highlights in Clinical Research and Healthcare for 2023 | Cromos Pharma
Key Highlights in Clinical Research and Healthcare for 2023
Clinical Intelligence Report 7th edition December
Revitalizing Biotech: Navigating Efficient Clinical Trials Amid Financial Constraints
FDA approved Gene Therapies for Sickle Cell Disease | Cromos Pharma
FDA Greenlights Groundbreaking Gene Therapies for Sickle Cell Disease
Clinical Research Focus #23 December | Cromos Pharma
Clinical Research Focus. 23rd Edition
Clinical Intelligence Report 6th edition November
Shining a Spotlight on Diabetes Awareness Month: The Vital Role of Clinical Trials
Navigating the Challenging Biotech Funding Landscape | Cromos Pharma
Navigating the Challenging Biotech Funding Landscape
Clinical Research Focus | 22nd Edition. November | Cromos Pharma
Clinical Research Focus. 22nd Edition
Cromos Pharma's CEO Reflections on ESMO 2023
Cromos Pharma’s CEO Reflections on ESMO 2023: A Glimpse into The Future Of Oncology
Fit-for-Purpose Biotech – CRO Collaboration – The FSP Model | Cromos Pharma
Fit-for-Purpose Biotech – CRO Collaboration: The FSP Model
Project Optimus - Enhancing Oncology Drug Dosage Optimization | Cromos Pharma
Enhancing Oncology Drug Dosage Optimization: Project Optimus
Clinical Research Focus | 21st Edition. October | Cromos Pharma
Clinical Research Focus. 21st Edition
Debating the Role of Interchangeability in Biosimilar Development
Debating the Role of Interchangeability in Biosimilar Development
Clinical Research Focus 20th Edition September | Cromos Pharma
Clinical Research Focus. 20th Edition
EMA Releases a Reflection Paper on the Role of AI in Drug Development
EMA Releases a Reflection Paper on the Role of AI in Drug Development
Regulatory Landscapes of GMO Research Programs | Cromos Pharma
Cromos Pharma Contemplates Complex International GMO Research Program Regulations